1. Antibody–drug conjugates come of age in oncology;Dumontet;Nat Rev Drug Discov,2023
2. A review of the current FDA-approved antibody-drug conjugates: landmark clinical trials and indications;Kesireddy;Pharm Med,2023
3. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target;Stepan;J Histochem Cytochem,2011
4. Trop2 is a potential biomarker for the promotion of EMT in human breast cancer;Zhao;Oncol Rep,2018
5. Trop2 binding IGF2R induces gefitinib resistance in NSCLC by remodeling the tumor microenvironment;Sun;J Cancer,2021